一种新型抗癌药物（LY186641）干扰肌酐测定。
A new anticancer agent (LY186641) interferes with creatinine assay.
作者信息
Bonnay M M, Recondo G, Gouyette A J, Armand J P
机构信息
Département de Biologie Clinique, Institut Gustave-Roussy, Villejuif,France.
出版信息
Cancer Chemother Pharmacol. 1989;23(2):119-20. doi: 10.1007/BF00273530.
PMID:2910508
Abstract
The administration of a diarylsulfonylurea, LY186641, which is presently undergoing a multicentric phase I clinical trial as an anticancer agent, produces major analytical interference with commonly used creatinine analysis techniques. We confirm that this interference is caused by a metabolite rather than the parent compound and propose an alternative, interference-free method.
摘要
二芳基磺酰脲类化合物LY186641作为一种抗癌药物目前正在进行多中心I期临床试验，其给药会对常用的肌酐分析技术产生重大分析干扰。我们证实这种干扰是由一种代谢物而非母体化合物引起的，并提出了一种无干扰的替代方法。
Zotero 插件